Patients who have undergone a kidney transplant and have high levels of serum uric acid symptomatic gout may benefit from treatment with pegloticase, according to a recent study.
Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More
ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…
Update on Extrapulmonary Sarcoidosis
Neurosarcoidosis & sarcoid dermatopathology are discussed.
Good Flow: 2021 Updates in Vasculitis
During the ACR Convergence 2021 annual Review Course, Peter Merkel, MD, MPH, provided recent updates on vasculitis.
Guselkumab Boosts Response in Resistant Psoriatic Arthritis
NEW YORK (Reuters Health)—In patients with psoriatic arthritis (PsA) who are resistant to tumor necrosis factor inhibitors (TNFi), guselkumab was more effective than placebo in a phase 3b trial. “Guselkumab is a relatively new treatment and is the first drug in its class (IL-23 inhibitor) to gain approval for PsA,” Dr. Laura Coates of the…
Tofacitinib Yields Rapid & Sustained Improvement in JIA
NEW YORK (Reuters Health)—Tofacitinib significantly reduces the number of flares in children with polyarticular course juvenile idiopathic arthritis (JIA), according to the first phase-3 clinical trial to assess the efficacy of a Janus kinase (JAK) inhibitor in JIA. JIA is a heterogeneous group of chronic conditions with no known cause that develop before age 16…
Telehealth Exercise & Diet Programs Curb Pain & Boost Function in Knee OA
NEW YORK (Reuters Health)—In patients with knee osteoarthritis (OA), telehealth-delivered exercise and diet programs are superior to electronic health information for reducing pain and improving function, although the contribution of diet is modest, a randomized trial shows.1 “This research provides evidence from a large clinical trial to help tease out how much benefit dietary weight…
Advances in Rheumatology & Challenges that Remain Spotlighted in ACR Convergence 2021 Closing Session
The diverse topics, research & perspectives from this year’s ACR Convergence bring new insights for rheumatologists & all who care for their patients, according to speakers at the meeting’s Closing Session.
Management of Inflammatory Myositis: Options for Refractory Disease & New Therapies Discussed
Options to escalate treatment for refractory inflammatory myositis and new therapies in the pipeline are discussed.
What Rheumatologists Should Know About Childhood-Onset SLE & Vasculitis
ACR CONVERGENCE 2021—Many of the effects of childhood-onset systemic lupus erythematosus (cSLE) and vasculitis carry into adulthood and present adult rheumatologists with key differences in managing these patients after their transition from a pediatric to an adult provider. “The young adult with childhood-onset lupus is similar in many ways to adults with lupus, but there…
- « Previous Page
- 1
- …
- 46
- 47
- 48
- 49
- 50
- …
- 330
- Next Page »